Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of chrysin to preparation of medicines for treating methicillin-resistant staphylococcus aureus infectious pneumonia

A staphylococcal infection and methicillin-resistant technology, applied in the direction of antibacterial drugs, drug combinations, pharmaceutical formulations, etc., can solve the problems of no cure, decreased antibiotic sensitivity, multi-drug resistance, etc., and achieve good protection effect Effect

Inactive Publication Date: 2019-07-19
JILIN UNIV
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] The purpose of the present invention is to solve the drug resistance or even multi-drug resistance of Staphylococcus aureus, and the sensitivity to antibiotics continues to decline, which leads to the problem that there is no cure for the treatment of Staphylococcus aureus infectious pneumonia. Application of a kind of chrysin in preparation of medicine for treating methicillin-resistant Staphylococcus aureus infectious pneumonia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of chrysin to preparation of medicines for treating methicillin-resistant staphylococcus aureus infectious pneumonia
  • Application of chrysin to preparation of medicines for treating methicillin-resistant staphylococcus aureus infectious pneumonia
  • Application of chrysin to preparation of medicines for treating methicillin-resistant staphylococcus aureus infectious pneumonia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] Example 1. Cytotoxicity test of chrysin on human lung epithelial cell A549:

[0017] MTT, 3-(4,5-dimethylthiazole-2)-2,5-diphenyltetrazolium bromide (trade name: Thiazole Blue), is a common reagent for testing cell viability and growth rate . In order to determine the effect of chrysin on cell growth and survival, this experiment used MTT method to determine the cytotoxicity of chrysin on human lung epithelial cells A549.

[0018] 1.1 Culture human lung epithelial cells A549 to the logarithmic growth phase, trypsinize and resuspend in DMEM / high glucose medium (containing 10% fetal bovine serum), adjust the cell suspension concentration, and add 150μL cell suspension per well (6×103 cells) were seeded into 96-well cell culture plates. Place the cell culture plate in a 37°C, 5% CO2 cell incubator.

[0019] 1.2 After the cells adhere to the wall, add different concentrations of chrysin (32μg / mL, 64μg / mL, 128μg / mL and 256μg / mL), set 3 replicates for each concentration, and cont...

Embodiment 2

[0023] Example 2. Chrysin inhibits the invasion of methicillin-resistant Staphylococcus aureus on human lung epithelial cells A549:

[0024] 2.1 Culture human lung epithelial cells A549 to the logarithmic growth phase, trypsinize and resuspend in DMEM / high glucose medium (containing 10% fetal bovine serum), adjust the cell suspension concentration to 4×104 cells / mL, and then take 500μL of cell suspension and add it to a 24-well cell culture plate (including cell slides). Place the cell culture plate in a cell incubator and incubate overnight at 37°C and 5% CO2.

[0025] 2.2 Cultivate Staphylococcus aureus to the logarithmic growth phase, inoculate it in a TSA medium containing the final concentration of 64μg / mL and 128μg / mL chrysin at 1:100, and continue to cultivate until the absorbance is OD600nm = 1.0 for use.

[0026] 2.3 Take 500 μL of Staphylococcus aureus suspension (absorbance of OD600nm = 1.0) from each drug concentration treatment group, and add them to the 24-well cell c...

Embodiment 3

[0030] Example 3. Experimental therapeutic study of Chrysin on Staphylococcus aureus pneumonia in mice:

[0031] 3.1 Establish a mouse model of methicillin-resistant Staphylococcus aureus infectious pneumonia

[0032] The MRSA strain of Staphylococcus aureus was picked from the agarose TSA plate, inoculated into TSA liquid medium, and cultured overnight at 37° C. and 200 rpm with shaking. On the next day, take 50μL of bacterial solution to 5mL fresh TSA medium, continue to culture to logarithmic phase, 5000rpm, centrifuge for 10 minutes, collect the bacterial pellet, wash twice with sterile PBS, adjust the concentration of the bacterial solution to 3.3×1010CFU / mL, spare.

[0033] Male SPF C57BL / 6 mice aged 6-8 weeks and weighing 8-22 g were selected and reared adaptively for 5 days to construct a mouse model of MRSA infectious pneumonia. For the mouse pneumonia lethality experiment, the mice were randomly divided into an uninfected group, an infected control group, and a 50 mg / kg ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of chrysin to preparation of medicines for treating methicillin-resistant staphylococcus aureus infectious pneumonia. The chrysin is also called chrysin, the chemical formula is C15H10O4, the chemical name is 5,7-hydrogen flavone and 5,7-dihydroxyflavone, and the chrysin is a flavonoid compound which is obtained through separation from bignoniaceae plant semen oroxyli and has extensive pharmacological activity. Pharmacological medicine research indicates that the chrysin has various pharmacological activity such as effects of resisting blood fat, resisting inflammation, resisting atherosclerosis and the like. The chrysin can be applied to preparation of medicines for treating the methicillin-resistant staphylococcus aureus infectious pneumonia, and has better protection effects on the methicillin-resistant staphylococcus aureus infectious pneumonia. The application disclosed by the invention has the beneficial effects that through human pulmonaryepithelial cell invasion experiment and a mouse staphylococcus aureus pneumonia model, the situation that the chrysin has protection effects on staphylococcus aureus infectious pneumonia is confirmed.

Description

Technical field [0001] The invention relates to an application of chrysin in the preparation of a medicine for treating infectious pneumonia, in particular to the application of chrysin in the preparation of a medicine for treating methicillin-resistant Staphylococcus aureus infectious pneumonia. Background technique [0002] Staphylococcus aureus is an important pathogen that often causes acute purulent pneumonia in adults and children. In clinical treatment, antibiotics such as oxacillin, cloxacillin, methicillin or vancomycin are generally used for treatment. However, under the selective pressure of antibiotics, bacteria have become resistant or even multi-drug resistant, and their sensitivity to antibiotics has continued to decline. At present, about 50% of Staphylococcus aureus pneumonia isolates are classified as methicillin-resistant Staphylococcus aureus (MRSA), making the treatment of Staphylococcus aureus infectious pneumonia incurable, making it a An important cause ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61P31/04A61P11/00
CPCA61K31/352A61P11/00A61P31/04
Inventor 石艳
Owner JILIN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com